News

Vertex Pharma said that the NDA submission for Telaprevir is supported by results from three Phase 3 studies, Advance, Illuminate and Realize, which evaluated Telaprevir in people chronically

Nutraceutical posted a net income of $3.54m for the fourth quarter 2010, or $0.34 per diluted share, compared to net income of $3.19m, or $0.29 per diluted share,

BDSI said that the shutdown was not related to Onsolis but involved concerns that had been expressed in a publicly available letter by the US Food and Drug

UCB claims that the Recover study is the first large-scale trial to investigate early morning motor function and sleep as coprimary outcome measures in Parkinson’s disease (PD). Data

According to ShangPharma, the revenue rises primarily due to a larger customer base, higher revenues from the company’s top customers, broader service offerings and higher average rate from

Welchol is indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia (Fredrickson Type IIa). Daiichi Sankyo and

Hemispherx Biopharma has published the results in the current issue of The Journal of Applied Research in which the report is entitled ‘Cardiac Toxicity in Chronic Fatigue Syndrome

Chimerix study demonstrated that treatment with CMX001reduced mortality rates and effectively inhibited HSV replication in a mouse model of disseminated infections and central nervous system infections. Notably, orally-administered

ConfiDisc said that the disc restricts the view of the user and disallows the proper injection angle needed for intravenous injection and is virtually impossible to inject at